Immuno-Oncology Frontiers World 2019

Topics

• Collaboration strategies: what do investors and big pharma want to see from biotech and academia in order to invest/partner?
• The value of immuno-oncology RD assets and how these therapies are shaping current and future oncology RD pipelines
• Overcoming hurdles in translation: what progress has been made in developing more informative pre-clinical models to provide real insights for the clinic?
• What will European market access strategy for CAR T cell therapies and combination therapies look like?
• The use of predictive biomarkers and their role in predicting patient response rates in the clinic
• Key scientific advancements from emerging immuno-oncology biotechs including coverage of oncolytic virus therapies, cancer vaccines, next-generation cellular immunotherapies, the tumour microenvironment, combination therapies and next-generation checkpoint inhibitors
• Clinical endpoints: how to ensure relevant/alternative surrogate endpoints are incorporated into immuno-oncology studies?
• The future for a busy immuno-oncology combination therapy marketplace - defining the clinical and commercial approaches that will be used when combining multiple therapies
• Highlighting key recent and forthcoming areas of EU regulatory guideline and legislation development what is need to know for the worlds immuno-oncology industry leaders?
• CAR T immunotherapies or bispecific antibodies?

Who should Attend

• VP Immunotherapy
• Venture Partner
• Cheif Scientific Officer
• Chief Executive Officer
• VP, Head of Translational Biomarkers
• VP & Managing Director
• Senior Director, Translational Oncology
• Programme Director, Scientific Affairs
• Senior Pharmaceutical Analyst and European Head
• Managing Director, European & Asian Operations
• Senior Director, Global Head Search & Evaluation Oncology
• VP, Head Search & Evaluation, Business Development